Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical-stage ophthalmic firm, announced its financial results for Q4 and full year 2020. It reported a net loss of $4.2 million in Q4, an improvement from $5.2 million in Q4 2019. Total revenue for the year was approximately $2.0 million, mainly from a licensing milestone. The FDA has accepted its NDA for MydCombi™, with a PDUFA date set for October 28, 2021. Additionally, patient enrollment in the Phase 3 VISION-1 study is complete, with topline data expected in Q2 2021. The company ended 2020 with $28.4 million in cash.
- FDA accepted NDA for MydCombi with PDUFA date of October 28, 2021.
- Completed patient enrollment in Phase 3 VISION-1 study for MicroLine.
- Licensed MicroPine for $10 million upfront and potential $35 million in milestones.
- Increased cash position to $28.4 million from $14.2 million year-over-year.
- Total revenue of approximately $2.0 million for 2020, with limited commercial activity.
- Net loss of $19.8 million for 2020, though improved from prior year.
Announces MydCombi expected PDUFA date of October 28, 2021
Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; topline data on track for Q2
Company to host conference call and webcast today, March 25, at 4:30 pm ET
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial results for the fourth quarter and full year ended December 31, 2020.
Fourth Quarter 2020 and Recent Business Highlights
- U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for the Company’s pupil dilation agent MydCombi™ and subsequently notified the Company that the expected PDUFA date is October 28, 2021.
- Completed patient enrollment in the Company’s Phase 3 VISION-1 study of MicroLine for the improvement in near vision in patients with presbyopia.
- Licensed MicroPine, an investigational treatment for the reduction of pediatric myopia progression in children ages 3-12, to Bausch Health for an upfront payment of
$10 million , up to$35 million in milestone payments, and royalties ranging from mid-single digit to mid-teen percentages of gross profit on sales in the U.S. and Canada. - Established exclusive collaboration and licensing agreement with Arctic Vision to develop and commercialize MicroPine and MicroLine, a Phase 3-ready treatment for presbyopia in Greater China and South Korea, with potential licensing and development payments of up to
$41.75 million , and additional royalty or supply payments. - Closed a public offering of the Company’s common stock for net proceeds of approximately
$12.5 million .
Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia, commented, “We have made significant progress during 2020 advancing our proprietary clinical programs. Most recently, we announced that the FDA has accepted our NDA for MydCombi, our proprietary fixed combination mydriatic, or pupil dilation agent, for potential use in the over 80 million comprehensive eye exams currently conducted each year in the United States. If approved, not only would MydCombi be the first microdosed ocular therapeutic applied with our proprietary high precision smart delivery system, the Optejet®, but it would transition us into a commercial stage company. We look forward to our PDUFA date on October 28.”
“Previously we announced that the first patient had been dosed in our VISION-1 Phase 3 clinical study evaluating our proprietary pilocarpine formulation, MicroLine, which is also delivered via the Optejet, for the improvement of near vision in patients with presbyopia, an estimated multi-billion-dollar indication. Today, we are pleased to report that we recently completed enrollment in VISION-1 and, as this is a relatively short study, we continue to anticipate topline data in the second quarter of this year. With our second Phase 3 program now initiated, an NDA accepted, and several robust development partnerships with ophthalmologic leaders established, we believe we have significant momentum. We look forward to building on this progress towards multiple potentially value creating milestones ahead,” concluded Dr. Ianchulev.
Fourth Quarter and Full Year 2020 Financial Review
For the fourth quarter of 2020, net loss was approximately
Total revenue was approximately
Research and development expenses totaled approximately
For the fourth quarter of 2020, general and administrative expenses were approximately
Total operating expenses for the fourth quarter of 2020 were approximately
As of December 31, 2020, the Company’s cash and cash equivalents were approximately
Conference Call and Webcast
The conference call is scheduled to begin at 4:30 pm ET on Thursday, March 25, 2021. Participants should dial 1-877-407-9039 (United States) or 1-201-689-8470 (International) with the conference code 13716228. A live webcast of the conference call will also be available on the Investor Relations page of the Company's corporate website at www.eyenovia.com.
The webcast will be archived on Eyenovia’s website for one year.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, visit www.eyenovia.com.
About MicroLine for Presbyopia
MicroLine is a pharmacologic treatment for presbyopia. Presbyopia is the non-preventable, age related hardening of the lens, which causes a gradual loss of the eye’s ability to focus on nearby objects and is estimated to affect nearly 113 million Americans. Current treatment options are typically device-based, such as reading glasses and contact lenses. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. Eyenovia believes that its administration of pilocarpine using the Company’s high precision microdosing technology could provide a meaningful improvement in near vision while enhancing tolerability and usability.
About MicroPine for Progressive Myopia
MicroPine (atropine ophthalmic solution) is Eyenovia’s investigational, potentially first-in-class topical treatment for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. It has been developed for comfort and ease-of-use in children, and its microdose administration is designed to potentially result in low systemic and ocular drug exposure.
About MicroStat (MyCombi™) for Mydriasis
MydCombi is Eyenovia's first-in-class fixed-combination micro-formulation product (tropicamide
About Optejet® and Microdose Array Print (MAP™) Therapeutics
Eyenovia's Optejet microdose formulation and delivery platform for ocular therapeutics uses high-precision piezo-print technology to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. We believe the volume of ophthalmic solution administered with the Optejet is less than
Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated regulatory review timing, and market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: fluctuations in our financial results; volatility and uncertainty in the global economy and financial markets in light of the evolving COVID-19 pandemic; our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our estimates regarding the potential market opportunity for our product candidates and potential revenue from licensing transactions; reliance on third parties; risks of our and our licensees’ clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the potential impacts of COVID-19 on our supply chain; the timing and our and our licensees’ ability to submit applications for, obtain and maintain regulatory approvals for our product candidates; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; reliance on third parties to develop and commercialize certain of our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for certain of our product candidates; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; intellectual property risks; our ability to attract and retain key personnel; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Diana Soltesz
Pazanga Health Communications
dsoltesz@pazangahealth.com
(818) 618-5634
| EYENOVIA, INC. | ||||||||
| Balance Sheets | ||||||||
| December 31, | ||||||||
| 2020 | 2019 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 28,371,828 | $ | 14,152,601 | ||||
| Deferred license costs | 1,600,000 | - | ||||||
| License receivable | 2,966,039 | - | ||||||
| Prepaid expenses and other current assets | 453,478 | 196,680 | ||||||
| Total Current Assets | 33,391,345 | 14,349,281 | ||||||
| Property and equipment, net | 396,380 | 230,538 | ||||||
| Security deposit | 119,035 | 117,800 | ||||||
| Total Assets | $ | 33,906,760 | $ | 14,697,619 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 1,461,665 | $ | 1,541,358 | ||||
| Accrued compensation | 1,150,672 | 916,873 | ||||||
| Accrued expenses and other current liabilities | 1,480,692 | 453,430 | ||||||
| Deferred rent - current portion | 7,809 | - | ||||||
| Deferred license fee | 14,000,000 | - | ||||||
| Notes payable - current portion | 97,539 | - | ||||||
| Total Current Liabilities | 18,198,377 | 2,911,661 | ||||||
| Deferred rent - non-current portion | 38,684 | 45,351 | ||||||
| Notes payable - non-current portion | 365,814 | - | ||||||
| Total Liabilities | 18,602,875 | 2,957,012 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' Equity: | ||||||||
| Preferred stock, | ||||||||
| 0 shares issued and outstanding as of December 31, 2020 and | ||||||||
| 2019, respectively | - | - | ||||||
| Common stock, | ||||||||
| 24,978,585 and 17,100,726 shares issued and outstanding | ||||||||
| as of December 31, 2020 and 2019, respectively | 2,498 | 1,710 | ||||||
| Additional paid-in capital | 92,742,306 | 69,409,949 | ||||||
| Accumulated deficit | (77,440,919 | ) | (57,671,052 | ) | ||||
| Total Stockholders' Equity | 15,303,885 | 11,740,607 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 33,906,760 | $ | 14,697,619 | ||||
| EYENOVIA, INC. | |||||||||||||||
| Condensed Statements of Operations | |||||||||||||||
| For the Three Months Ended | For the Years Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| (unaudited) | (unaudited) | (unaudited) | |||||||||||||
| Operating Income | |||||||||||||||
| Revenue | $ | 2,000,000 | $ | - | $ | 2,000,000 | $ | - | |||||||
| Cost of revenue | (800,000 | ) | - | (800,000 | ) | - | |||||||||
| Gross Profit | 1,200,000 | - | 1,200,000 | - | |||||||||||
| Operating Expenses: | |||||||||||||||
| Research and development | $ | 3,350,521 | $ | 3,324,335 | $ | 13,263,817 | $ | 14,102,449 | |||||||
| General and administrative | 2,056,097 | 1,964,487 | 7,725,408 | 7,206,095 | |||||||||||
| Total Operating Expenses | 5,406,618 | 5,288,822 | 20,989,225 | 21,308,544 | |||||||||||
| Loss From Operations | (4,206,618 | ) | (5,288,822 | ) | (19,789,225 | ) | (21,308,544 | ) | |||||||
| Other Income (Expense): | |||||||||||||||
| Small Business Administration Economic | |||||||||||||||
| Injury Disaster Grant | - | - | 10,000 | ||||||||||||
| Interest expense | (2,065 | ) | - | (17,042 | ) | - | |||||||||
| Interest income | 1,821 | 47,338 | 26,400 | 151,786 | |||||||||||
| Net Loss | $ | (4,206,862 | ) | $ | (5,241,484 | ) | $ | (19,769,867 | ) | $ | (21,156,758 | ) | |||
| Net Loss Per Share | |||||||||||||||
| - Basic and Diluted | $ | (0.17 | ) | $ | (0.31 | ) | $ | (0.94 | ) | $ | (1.47 | ) | |||
| Weighted Average Number of | |||||||||||||||
| Common Shares Outstanding | |||||||||||||||
| - Basic and Diluted | 24,891,184 | 17,100,726 | 21,054,706 | 14,349,738 | |||||||||||
FAQ
What are Eyenovia's financial results for Q4 2020?
What is the expected PDUFA date for Eyenovia's MydCombi?
What revenue did Eyenovia generate in 2020?
What is the status of Eyenovia's VISION-1 study?
How much cash does Eyenovia have as of December 31, 2020?
